Evaluating HPG80 for Diagnosing Neuroendocrine Tumors in MEN1 Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the value of HPG80, a circulating progastrin marker, in diagnosing neuroendocrine tumors (NETs) in patients with a confirmed MEN1 mutation. MEN1 is a hereditary condition characterized by multiple endocrine tumors, and the study will involve collecting blood samples from eligible patients to analyze the presence of HPG80. The goal is to improve diagnostic accuracy for NETs associated with MEN1, which can significantly impact patient management and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with proven MEN1, symptomatic or not, confirmed on the basis of the following international criteria (Thakker et al.):
* patients with an MEN1 mutation;
* patients belonging to an identified MEN1 family in which at least one first-degree relative has been affected and has at least one MEN1-related lesion;
* patients without a positive genetic test or a family history of the disease, but with at least two of the three main MEN1 lesions (parathyroid adenomas, duodenopancreatic NETs and pituitary tumours).
* Majors patients,
* Patients who have undergone thoracoabdominal imaging (MRI, and/or CT and/or somatostatin receptor imaging (PET or octreotide scan)) within 3 months prior to inclusion or are due to undergo imaging within 3 months of inclusion to document the presence of NETs,
* Regardless of the treatment they are receiving (treatment naïve or treated patient),
* Regardless of the type of disease associated with MEN1 (presence or absence of NET, adenoma....),
* Patients who did not object to taking part in the study.

Exclusion Criteria:

* Person not affiliated to national health insurance
* Person subject to a measure legal protection (curatorship, guardianship, family empowerment) or a court order
* Pregnant, parturient or breastfeeding mothers

Where it's running

• Chu Dijon Bourgogne
  Dijon, France Recruiting

Study contacts

• Study coordinator: Côme LEPAGE
• Email: come.lepage@chu-dijon.fr
• Phone: 0380293750

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New DLL3 PET/CT imaging for neuroendocrine tumors compared with standard scans

  A new PET/CT scan using the 68Ga-DLL3 nanobody is being tested to see if it detects metastatic neuroendocrine tumors better than current scans in adults.

  Recruiting at 2 sites Phase 2 Peking University First Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07733024

• CTX-471 for NCAM-positive metastatic neuroendocrine tumors

  A phase 2 trial is testing CTX-471 in adults with NCAM (CD56) positive metastatic neuroendocrine tumors that have progressed after standard therapy.

  Recruiting at 2 sites Phase 2 Compass Therapeutics · St Louis, Missouri and 1 other locations · NCT07684170

• Terbium-161 DOTATATE for metastatic gastro‑enteropancreatic neuroendocrine tumors

  This trial tests terbium-161 DOTATATE, a targeted radioactive drug, in adults with metastatic well-differentiated GEP‑NETs who have progressed after lutetium‑177 therapy.

  Recruiting at 2 sites Phase 2 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07404176

• Sapu003 with or without exemestane for advanced mTOR-sensitive solid tumors

  This phase 1b test will try weekly IV Sapu003, given with exemestane for HR+/HER2- breast cancer or alone for other mTOR-sensitive advanced tumors, to see if it's safe and how your body handles it.

  Recruiting Phase 1 Sapu Nano (Us) LLC · Adelaide · NCT07369505

• Safety and tolerability of NEUK203-13 CAR-NK cells for DLL3 in advanced neuroendocrine tumors

  This early phase trial tests NEUK203-13, an off-the-shelf CAR-NK cell therapy, in adults with advanced SCLC or other neuroendocrine tumors to see if it is safe and if it shows any anti-tumor activity.

  Recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07366658

• Cabozantinib for adults with previously treated neuroendocrine tumors

  This study will see how cabozantinib works and how safe it is for adults with neuroendocrine tumors that have continued to grow after prior systemic treatment.

  Recruiting at 23 sites Ipsen · Graz and 40 other locations · NCT07314164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.